阿德福韦酯治疗慢性乙型肝炎的疗效观察

The observation of curative effect of Adefovir Dipivoxil for Chronic Hepatitis B.

目的阿德福韦酯与拉米夫定治疗慢性乙型肝炎的疗效观察。方法将90例患者随机分为两组,每组45人,A组(阿德福韦酯组)给予阿德福韦酯10mg,1次/d,疗程12～24个月,平均为14.5个月;B组(拉米夫定组)给予拉米夫定100mg,1次/d。结果 A、B组HBV-DNA阴转率、HBeAg转阴率、HBeAg和抗HBe血清转换率、ALT复常率分别为64.4%、42.2%、37.8%、88.9%和62.2%、44.4%、33.3%、62.2%,不良反应发生率均为2.2%,两组无统计学差异,P>0.05;耐药性A组与B组有统计学差异,P<0.05。结论阿德福韦酯耐药性低、ALT复常率高、安全性好。

Objective To observe clinical effect of lamivudine and adefovir dipivoxil on the patients with chronic hepatitis B.Methods 90 patients were randomly divided into 2 groups:45 patients in each group.Group A were taken adefovir dipivoxil 10 mg once a day,for 12～24 months(the mean of 14.5 months);The group B were administrated with lamivudine 100 mg once a day.RusuIts The clinical status,the effect and the negative rate of HBV-DNA,the negative rate of HbeAg,the negative rate of HbeAg and anti-Hbe,normalization rate of ALT in each group was 64.4%、42.2%、37.8%、88.9%and 62.2%、44.4%、33.3%、62.2%,the incidence of side reaction was 2.2%,were not statistical difference between groups A and B,P>0.05;and there were differences of drug-resistance between the two groups,P<0.0S.Conclusion The adefovir dipivoxil had characteristics of low drug-resistance,high normalization rate and safety.